VIVUS LLC

Achieve Life Sciences, Inc. appointed Mark K. Oki as Chief Financial Officer on December 5, 2024, with an annual base salary of $450,000 and potential bonuses, stock options, and restricted stock units.

Achieve Life Sciences appoints Mark Oki as CFO to oversee financial strategy and operations, aiming to commercialize cytisinicline for nicotine dependence. Oki's experience in biopharma will support the potential first new treatment in two decades, addressing a global health crisis.

The premature ejaculation treatment market is projected to grow by USD 1.46 billion from 2024-2028, driven by high efficacy of off-label drugs and nanotechnology advancements. Key players include A. Menarini, Absorption Pharmaceuticals, Alembic Pharmaceuticals, and others. Challenges include side effects and pandemic-related access issues, with AI and telemedicine offering potential solutions.

GLP-1s in high demand due to CV benefits; new obesity drugs in later-stage trials, FDA approval predicted for 2027.

VIVUS and UpScriptHealth launch ChooseQ.online, a telehealth platform for QSYMIA, a leading weight loss medication, enhancing patient access and convenience.

Tirzepatide and semaglutide outperform other FDA-approved drugs for weight loss, according to a network meta-analysis in 'Obesity'. Tirzepatide 15 mg and semaglutide 2.4 mg showed superior efficacy with no significantly higher risk of adverse events.